Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRBP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRBPCorbus Pharmaceuticals$8.41+1.5%$7.39$4.64▼$61.90$102.88M3.11347,269 shs4,718 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRBPCorbus Pharmaceuticals-5.26%-10.39%+12.81%+37.31%-81.27%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRBPCorbus Pharmaceuticals3.9738 of 5 stars3.61.00.04.71.62.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRBPCorbus Pharmaceuticals 3.10Buy$50.88505.29% UpsideCurrent Analyst Ratings BreakdownLatest CRBP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/7/2025CRBPCorbus PharmaceuticalsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/7/2025CRBPCorbus PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$65.00 ➝ $58.005/7/2025CRBPCorbus PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$60.00 ➝ $56.005/7/2025CRBPCorbus PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$50.00 ➝ $40.00(Data available from 6/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRBPCorbus PharmaceuticalsN/AN/AN/AN/A$11.69 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRBPCorbus Pharmaceuticals-$40.21M-$4.22N/AN/AN/AN/A-36.87%-32.87%8/5/2025 (Estimated)Latest CRBP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2025Q1 2025CRBPCorbus Pharmaceuticals-$1.26-$1.39-$0.13-$1.39N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRBPCorbus PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRBPCorbus PharmaceuticalsN/A11.8211.82Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRBPCorbus Pharmaceuticals64.64%Insider OwnershipCompanyInsider OwnershipCRBPCorbus Pharmaceuticals4.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRBPCorbus Pharmaceuticals4012.24 million11.75 millionOptionableCRBP HeadlinesRecent News About These CompaniesCorbus Pharmaceuticals: Is Its Pipeline Really Worthless After Novo's Negative Data?June 17 at 4:15 PM | seekingalpha.comCorbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Receives Average Recommendation of "Buy" from AnalystsJune 12, 2025 | marketbeat.comNuveen Asset Management LLC Has $341,000 Stake in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP)June 6, 2025 | marketbeat.comTwo Sigma Investments LP Purchases 91,205 Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP)June 4, 2025 | marketbeat.comAnne Altmeyer Sells 1,392 Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) StockJune 3, 2025 | marketbeat.comInsider Selling: Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Director Sells 2,783 Shares of StockJune 3, 2025 | marketbeat.comCorbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Director Sells $10,092.00 in StockJune 3, 2025 | insidertrades.comCorbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Shares Acquired by Millennium Management LLCMay 30, 2025 | marketbeat.com3 Stocks Targeting Weight Loss Market With Cannabinoid-Based TherapiesMay 23, 2025 | zacks.comMizuho Securities Sticks to Its Buy Rating for Corbus Pharmaceuticals (CRBP)May 22, 2025 | theglobeandmail.comCorbus Pharmaceuticals to Present at the Jefferies Global Healthcare ConferenceMay 22, 2025 | globenewswire.comTang Capital Management LLC Has $2.86 Million Stake in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP)May 20, 2025 | marketbeat.comCorbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Given Average Rating of "Buy" by AnalystsMay 20, 2025 | marketbeat.comCorbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board ChairMay 19, 2025 | finance.yahoo.comIs Small-Cap Corbus Pharma a Worthy Cannabis Investment?May 16, 2025 | zacks.comWhy Corbus Pharmaceuticals Holdings, Inc.’s (CRBP) Stock Is Up 5.55%May 10, 2025 | aaii.comCorbus Pharmaceuticals to Present at the 2025 RBC Capital Markets Global Healthcare ConferenceMay 8, 2025 | finance.yahoo.comCorbus Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides a Corporate UpdateMay 7, 2025 | finance.yahoo.com3 Unconventional Cannabis Stocks to Watch in 2025April 29, 2025 | zacks.comWe Think Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Can Afford To Drive Business GrowthApril 18, 2025 | finance.yahoo.comWall Street Analysts See a 764.18% Upside in Corbus Pharmaceuticals (CRBP): Can the Stock Really Move This High?April 18, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCRBP Company DescriptionsCorbus Pharmaceuticals NASDAQ:CRBP$8.40 +0.13 (+1.51%) As of 10:32 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Qualcomm: A Technical Setup Is Emerging, and It's Bullish Microsoft-OpenAI Rift May Cap Stock Upside Potential Jabil Stock Hits Highs on AI Tailwinds and Strong Buybacks Analyst Downgrades Joby, But Overlooks Major Regulatory Wins Applied Digital: Now the High-Stakes Race to Build Begins Why SailPoint May Cruise Past Cybersecurity Rivals in 2025 Zscaler Upgraded: Wall Street Forecasts 26% More Upside Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
